September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
An overview of medical practices in neovascular age-related macular degeneration: evaluating the changes in France between 2013 and 2016
Author Affiliations & Notes
  • Nathalie San Nicolas
    Novartis Pharma SAS, Rueil-Malmaison, France
  • Vincent Gualino
    Ophtalmology, Clinique Honoré Cave, Montauban, France
  • Jennyfer Zerbib
    Ophtalmology, Private practice, Nice, France
  • Typhaine Grenet
    Centre Imagerie et Laser, Paris, France
  • Maté Streho
    Centre Exploration de la Vision, Rueil-Malmaison, France
  • Jeremy Halfon
    Cabinet D'ophtalmologie des Halles de Tours, Tours, France
  • Pierre-Louis Cornut
    Pôle Vision, Clinique Du Val d'Ouest, Lyon, France
  • Alexandre Bourhis
    Ophtalmology, Polyclinique de L'Atlantique, Saint-Herblain, France
  • Camille Maurin
    Novartis Pharma SAS, Rueil-Malmaison, France
  • Helene Masse
    Ophtalmology, CHU Nantes, Nantes, France
  • Footnotes
    Commercial Relationships   Nathalie San Nicolas, Novartis Pharma SAS (E); Vincent Gualino, Alcon (C), Allergan (C), Bayer (C), Novartis (C); Jennyfer Zerbib, Novartis (C); Typhaine Grenet, Allergan (C), Bayer (C), Novartis (C); Maté Streho, Allergan (C), Bayer (C), Novartis (C); Jeremy Halfon, Novartis (C); Pierre-Louis Cornut, None; Alexandre Bourhis, Novartis (C); Camille Maurin, Novartis Pharma SAS (E); Helene Masse, Novartis (C)
  • Footnotes
    Support  Novartis Pharma SAS
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3354. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nathalie San Nicolas, Vincent Gualino, Jennyfer Zerbib, Typhaine Grenet, Maté Streho, Jeremy Halfon, Pierre-Louis Cornut, Alexandre Bourhis, Camille Maurin, Helene Masse; An overview of medical practices in neovascular age-related macular degeneration: evaluating the changes in France between 2013 and 2016. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3354.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The LYVE survey employed a unique design that used two databases in France to evaluate the frequency of ranibizumab (RBZ) and aflibercept (AFL) deliveries over the 12-month follow-up period for treatment-naïve patients with neovascular age-related macular degeneration (nAMD) in routine medical practice.

Methods : A quantitative internet survey among 150 ophthalmologists in France (general ophthalmologists, 90; retinal specialists, 60) will be conducted in January 2016. Quantitative questions are developed by a committee of experts. Most questions are similar to those included in the 2013 and 2015 surveys. These questions evaluate: i) diagnosis, treatment, and follow-up parameters, ii) logistical organization and access to care for nAMD patients, and iii) current treatment protocols.

Results : Data from the 2013 and 2015 surveys showed that treatment regimens used by retinal specialists are highly variable. However, the treat and extend (T&E) regimen was more popular in 2015 compared with 2013 (17% vs 4%). In the 2013 survey, the effectiveness of the treatment initiation phase was assessed using optical coherence tomography (OCT) in 70% of the cases and visual acuity (VA) test in 100% of the cases; in 2015, it was assessed using OCT in 99% of the cases and the VA test in 89% of the cases. In comparison with these data, the results of the 2016 survey will show if the management of nAMD has changed from 2013 through 2016.

Conclusions : Comparison of the results from the 2013, 2015, and 2016 surveys will provide new insights on the management of nAMD patients in France. The 2016 results are expected in March 2016.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.